AAGH: AI 评分 56/100 — AI 分析 (4月 2026)

America Great Health is a biotechnology company focused on researching and developing protein and peptide small molecular drugs. The company also manufactures and sells AI cloud computing-based diagnostic and medical devices, cell therapy, regenerative medicine, and supplements.

Key Facts: AI Score: 56/100 Sector: Healthcare

公司概况

概要：

America Great Health, a biotechnology company established in 2013, focuses on the research and development of protein and peptide small molecular drugs, alongside manufacturing AI cloud computing-based diagnostic devices, cell therapies, and regenerative medicine, positioning itself within the competitive healthcare sector.

AAGH是做什么的？

America Great Health, founded in 2013 and headquartered in Alhambra, California, operates as a biotechnology company focused on the research, development, and manufacturing of innovative healthcare solutions. Originally known as Crown Marketing, the company transitioned to America Great Health in March 2017, signaling a strategic shift towards biotechnology. The company's core activities include the research and development of protein and peptide small molecular drugs, targeting various therapeutic areas. Additionally, America Great Health manufactures and sells AI cloud computing-based diagnostic and medical devices, leveraging artificial intelligence to enhance diagnostic accuracy and efficiency. The company is also involved in cell therapy and regenerative medicine, exploring advanced treatments for various diseases and conditions. Furthermore, America Great Health offers a range of supplements, catering to the growing demand for health and wellness products. With a small team of 5 employees, the company focuses on innovation and technological advancement within the biotechnology sector.

AAGH的投资论点是什么？

America Great Health presents a high-risk, high-reward investment opportunity within the biotechnology sector. Key value drivers include the successful development and commercialization of its protein and peptide small molecular drugs, as well as the adoption of its AI cloud computing-based diagnostic devices. The company's focus on cell therapy and regenerative medicine also offers long-term growth potential. However, the company's negative profit margin of -173.0% and high beta of 6.35 indicate significant financial risks. The absence of a dividend further reduces its attractiveness to income-seeking investors. Upcoming catalysts include potential breakthroughs in its drug development pipeline and partnerships for its AI-based diagnostic devices. Investors should carefully consider the company's financial stability and the competitive landscape before investing.

AAGH在哪个行业运营？

America Great Health operates within the dynamic and competitive biotechnology industry, characterized by rapid innovation and evolving market trends. The industry is driven by advancements in genomics, proteomics, and personalized medicine. The market for AI-based diagnostic devices is experiencing significant growth, fueled by the increasing adoption of artificial intelligence in healthcare. Competitors like ADXS, AGNPF, AGTX, APLIF, and HESG are also vying for market share in the biotechnology and pharmaceutical sectors. America Great Health's success depends on its ability to differentiate itself through innovative products and strategic partnerships.

Biotechnology

Healthcare

AAGH有哪些增长机遇？

Expansion of AI-Based Diagnostic Devices: The market for AI in healthcare diagnostics is projected to reach $6.7 billion by 2026, offering a significant growth opportunity for America Great Health. By leveraging its AI cloud computing-based diagnostic devices, the company can tap into this growing market. Successful development and commercialization of these devices could drive revenue growth and improve profitability. Timeline: Ongoing.
Development of Protein and Peptide Small Molecular Drugs: The global market for peptide therapeutics is expected to reach $41.8 billion by 2028. America Great Health's focus on researching and developing protein and peptide small molecular drugs positions it to capitalize on this growing market. Successful clinical trials and regulatory approvals could lead to significant revenue streams. Timeline: Ongoing.
Cell Therapy and Regenerative Medicine: The regenerative medicine market is projected to reach $53.6 billion by 2025. America Great Health's involvement in cell therapy and regenerative medicine offers long-term growth potential. Advances in these fields could lead to breakthrough treatments for various diseases and conditions. Timeline: Ongoing.
Strategic Partnerships and Collaborations: Forming strategic partnerships with pharmaceutical companies, research institutions, and healthcare providers can accelerate the development and commercialization of America Great Health's products. Collaborations can provide access to funding, expertise, and distribution channels. Timeline: Ongoing.
Expansion into International Markets: Expanding into international markets, particularly in Asia and Europe, can broaden America Great Health's customer base and revenue streams. Adapting its products and services to meet the needs of different markets can drive growth. Timeline: Ongoing.

America Great Health operates with a small team of 5 employees, indicating a lean operational structure.
The company's negative P/E ratio of -4.26 reflects its current lack of profitability.
AAGH's profit margin of -173.0% highlights significant financial challenges and operational inefficiencies.
The company boasts a high gross margin of 91.1%, suggesting strong pricing power on its existing products.
AAGH's high beta of 6.35 indicates substantial volatility compared to the overall market.

AAGH提供哪些产品和服务？

Researches and develops protein and peptide small molecular drugs.
Manufactures and sells AI cloud computing-based diagnostic and medical devices.
Engages in cell therapy research and development.
Develops regenerative medicine technologies.
Offers a range of health and wellness supplements.
Leverages AI to enhance diagnostic accuracy and efficiency.

AAGH如何赚钱？

Generates revenue through the sale of AI cloud computing-based diagnostic and medical devices.
Seeks to generate revenue through the sale of protein and peptide small molecular drugs upon successful development and regulatory approval.
Aims to generate revenue from cell therapy and regenerative medicine products and services.
Generates revenue through the sale of supplements.

Hospitals and clinics utilizing AI-based diagnostic devices.
Research institutions involved in drug development and clinical trials.
Patients seeking cell therapy and regenerative medicine treatments.
Consumers purchasing health and wellness supplements.

Proprietary AI cloud computing-based diagnostic technology.
Intellectual property related to protein and peptide small molecular drugs.
Expertise in cell therapy and regenerative medicine.
Established brand reputation in the health and wellness supplement market.

什么因素可能推动AAGH股价上涨？

Upcoming: Potential breakthroughs in the development of protein and peptide small molecular drugs.
Upcoming: Successful clinical trials and regulatory approvals for new drugs and devices.
Ongoing: Expansion of AI-based diagnostic devices in the healthcare sector.
Ongoing: Strategic partnerships and collaborations with larger companies.
Ongoing: Growth in the cell therapy and regenerative medicine market.

AAGH的主要风险是什么？

Potential: Intense competition in the biotechnology and pharmaceutical industries.
Potential: Regulatory hurdles and lengthy approval processes for new drugs and devices.
Potential: Patent expiration and generic competition.
Ongoing: Negative profit margin of -173.0% indicates financial instability.
Ongoing: Limited financial resources for research and development.

AAGH的核心优势是什么？

Focus on innovative technologies like AI and cell therapy.
High gross margin of 91.1% indicates strong pricing power.
Potential for breakthrough discoveries in drug development.
Established presence in the health and wellness supplement market.

AAGH的劣势是什么？

Negative profit margin of -173.0% indicates financial instability.
Small team of 5 employees limits operational capacity.
Limited financial resources for research and development.
High beta of 6.35 indicates significant market volatility.

AAGH有哪些机遇？

Expansion of AI-based diagnostic devices in the healthcare sector.
Development and commercialization of protein and peptide small molecular drugs.
Growth in the cell therapy and regenerative medicine market.
Strategic partnerships and collaborations with larger companies.

AAGH面临哪些威胁？

Intense competition in the biotechnology and pharmaceutical industries.
Regulatory hurdles and lengthy approval processes for new drugs and devices.
Patent expiration and generic competition.
Economic downturns and reduced healthcare spending.

AAGH的竞争对手是谁？

Advaxis, Inc. — Focuses on immunotherapy products. — (ADXS)
Agripharm Corp. — Operates in the cannabis industry. — (AGNPF)
Argenix N.V. — Develops antibody-based therapies. — (AGTX)
Applied DNA Sciences Inc — Provides DNA-based security and authentication solutions. — (APLIF)
Hesco Bastion Inc — Provides protective barriers and security solutions. — (HESG)

Key Metrics

MoonshotScore: 56/100

Company Profile

CEO: Mike Qingkun Wang
Headquarters: Alhambra, US
Employees: 5
Founded: 2012

AI Insight

AI analysis pending for AAGH

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does America Great Health do?

America Great Health operates as a biotechnology company focused on the research, development, and manufacturing of innovative healthcare solutions. The company's core activities include the research and development of protein and peptide small molecular drugs, targeting various therapeutic areas. Additionally, America Great Health manufactures and sells AI cloud computing-based diagnostic and medical devices, leveraging artificial intelligence to enhance diagnostic accuracy and efficiency. The company is also involved in cell therapy and regenerative medicine, exploring advanced treatments for various diseases and conditions. Furthermore, America Great Health offers a range of supplements, catering to the growing demand for health and wellness products.

What do analysts say about AAGH stock?

Currently, there is no available analyst coverage for America Great Health (AAGH) due to its OTC listing and small market capitalization. Key valuation metrics such as price targets and ratings are not available. Investors should conduct their own thorough research and due diligence before considering an investment in AAGH. Factors to consider include the company's financial performance, growth prospects, and the risks associated with investing in OTC stocks. The absence of analyst coverage underscores the need for independent assessment and caution.

What are the main risks for AAGH?

Investing in America Great Health carries significant risks, primarily stemming from its OTC listing and financial instability. The company's negative profit margin of -173.0% and high beta of 6.35 indicate substantial financial challenges and market volatility. Limited financial disclosure and transparency on the OTC market increase the risk of fraud or manipulation. Regulatory hurdles and lengthy approval processes for new drugs and devices pose additional challenges. Competition in the biotechnology and pharmaceutical industries is intense, and patent expiration could impact future revenue streams.